Consistent with previous studies, which have demonstrated that combined treatment with anti-SIGLEC9 and anti-PD-1/PD-L1 enhances anti-tumor efficacy, these findings further support the potential role of SIGLEC9 in immune-based therapies for cervical cancer.30 The gene discussed is CD274; the disease is cervical carcinoma.